Tacrolimus Concentrations Measured in Excreted Bile in Liver Transplant Recipients The STABILE Study

Autor: Eric Bellissant, Laurent Sulpice, Jean-Marie Beaurepaire, Karim Boudjema, Alexandre Chebaro, C. Cusumano, Edouard Bardou-Jacquet, Camille Tron, Antoine Petitcollin, P. Houssel-Debry, Véronique Desfourneaux, Bernard Meunier, Marc Blondeau, Michel Rayar, Clara Locher, M. Lakehal, Florian Lemaitre, Marie Clémence Verdier, Christophe Camus
Přispěvatelé: Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Comité de la Recherche Clinique et Translationnelle, Rennes University Hospital, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
Male
medicine.medical_specialty
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
chemical and pharmacologic phenomena
Liver transplantation
030226 pharmacology & pharmacy
01 natural sciences
Gastroenterology
Peripheral blood mononuclear cell
03 medical and health sciences
0302 clinical medicine
Therapeutic index
stomatognathic system
Internal medicine
medicine
Bile
Humans
bile quantification
Pharmacology (medical)
neurologic toxicity
tacrolimus
Whole blood
Aged
Pharmacology
medicine.diagnostic_test
liver transplantation
Surrogate endpoint
business.industry
010401 analytical chemistry
Middle Aged
Tacrolimus
0104 chemical sciences
3. Good health
Hepatobiliary Elimination
stomatognathic diseases
Immunosuppressive drug
Liver
Therapeutic drug monitoring
Leukocytes
Mononuclear
Female
Drug Monitoring
business
Immunosuppressive Agents
Zdroj: Clinical Therapeutics
Clinical Therapeutics, Elsevier, 2018, 40 (12), pp.2088-2098. ⟨10.1016/j.clinthera.2018.10.015⟩
Clinical Therapeutics, 2018, 40 (12), pp.2088-2098. ⟨10.1016/j.clinthera.2018.10.015⟩
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2018.10.015⟩
Popis: International audience; Purpose - Tacrolimus (TAC) is the main immunosuppressive drug in liver transplantation. Despite intensive therapeutic drug monitoring (TDM) that relies on whole blood trough concentration (TAC), patients still present with acute cellular rejection or TAC-related toxic effects with concentrations within the therapeutic range. TAC concentration in peripheral blood mononuclear cells (TAC) is considered as an efficient surrogate marker of TAC efficacy. However, it is still not applicable in daily practice. New TDM methods are therefore needed, especially during the early postoperative period. TAC is metabolized in the liver and eliminated through biliary excretion. We therefore hypothesised that TAC concentration measured in excreted bile (TAC) could be a relevant surrogate marker of its efficacy. Methods - The Therapeutic Drug Monitoring of Tacrolimus Biliary Concentrations for Liver-Transplanted Patients (STABILE) study is a prospective monocentric trial. During the 7 first days after TAC therapy initiation, TAC was measured. The correlation between TAC and TAC as well as between TAC and TAC was assessed. The correlations between TAC and liver graft function parameter or with occurrence of neurologic toxic effects were also evaluated. Findings - Between May 2016 and April 2017, 41 patients were analyzed. TAC was significantly correlated with TAC (r = 0.25, P = 0.007). However, a better correlation was found between TAC and TAC (r = 0.53, P
Databáze: OpenAIRE
Externí odkaz: